Introduction
============

Hepatocellular carcinoma (HCC) is the predominant cancer type among the primary liver cancers. Among the malignant tumors, HCC is the sixth most common cancer and is associated with fourth highest cancer-related mortality ([@ref-2]). In 2008, approximately 840,000 new cases of HCC were recorded globally, which resulted in approximately 780,000 deaths ([@ref-2]). In China, more than 466,100 new HCC cases and 422,100 HCC-related deaths were reported in 2015 ([@ref-6]). Nowadays, rapid advances has been made in the therapy of HCC thanks to the encouraging progress in early diagnosis and cancer therapeutic methods such as imaging techniques, liver transplantation, surgical resection, local ablation, and transcatheter arterial chemoembolization and comprehensive therapy ([@ref-28]). However, the 5-year survival rate of patients with HCC remains low due to the high rates of local recurrence and distant metastasis ([@ref-1]). Several studies have demonstrated that various aberrantly expressed genes can be used to determine HCC prognosis ([@ref-7]; [@ref-10]; [@ref-26]; [@ref-29]). For example, low expression of CTC-297N7.9 is associated with poor prognosis in HCC patients, and could be used as an independent prognostic indicator in HCC patients. However, its diagnostic capability is limited in discriminating HCC tissues from normal tissues with an AUC of 0.74 ([@ref-29]). The knockdown of TMEM16A inhibited HCC cell proliferation, migration and induced cell apoptosis, and upregulation of TMEM16A induced HCC cell growth, migration and reduced cell apoptosis ([@ref-27]). However, its diagnostic capability in discriminating HCC tissues from normal tissues was unknown. Currently, serum alpha-fetoprotein is the most reliable HCC biomarker although it has low sensitivity and specificity in the diagnosis of HCC ([@ref-3]; [@ref-9]). Therefore, there is an urgent need to identify and validate novel reliable diagnostic and prognostic biomarkers for HCC.

Spindle pole body component 25 (SPC25), a component of the nuclear division cycle 80 (Ndc80) complex, is involved in kinetochore-microtubule interactions and spindle checkpoint activity ([@ref-15]; [@ref-21]). Previous studies have reported that dysregulated SPC25 expression is associated with the oncogenic process and malignant phenotypes of several cancers. The upregulated expression of SPC25 has been reported in colorectal, gastric cancers, breast, and lung adenocarcinoma. Additionally, SPC25 is involved in carcinogenesis, cancer cell growth, and metastasis ([@ref-5]; [@ref-13]; [@ref-14]; [@ref-23]). A cell-based assay revealed that the SPC25 can be a potential biomarker for Alzheimer's disease as the expression level of SPC25 was significantly upregulated in the serum samples of patients with mild cognitive impairment ([@ref-28]). In the HCC cells, PRC1 regulates the expression and function of recurrence-associated genes, such as SPC25, KIF11 FANCI, and KIF23 via Wnt signalling ([@ref-29]). However, the correlation between SPC25 expression and HCC for diagnosis and prognosis of HCC has not been previously evaluated. This study aimed to analyze the SPC25 mRNA expression patterns and to determine the diagnostic and prognostic values of SPC25 expression in HCC.

In his study, we evaluated the mRNA expression of SPC25 in patients with HCC based on the data obtained from The Cancer Genome Atlas (TCGA) database. Additionally, the correlation between SPC25 expression and clinicopathological features, as well as the potential diagnostic and prognostic values of SPC25 in patients with HCC were analyzed. Furthermore, TCGA analysis results were validated using an external cohort from the International Cancer Genome Consortium (ICGC) database. A nomogram prognostic model based on SPC25 was constructed. The accuracy of the prognostic model was compared with that of the currently used American Joint Committee on Cancer (AJCC) staging system in both cohorts.

Material and Methods
====================

SPC25 expression data and clinicopathological characteristics
-------------------------------------------------------------

The gene expression profiles of 374 human HCC tissues and 50 non-neoplastic tissues, as well as the clinical data of patients, such as age at diagnosis, sex, histologic grade, pathological stage, vascular invasion, family history of cancer, survival status, and survival time were downloaded from TCGA Liver Hepatocellular Carcinoma (TCGA-LIHC; <https://portal.gdc.cancer.gov/>) database. The mRNA expression levels of SPC25 in TCGA cohort were extracted. The expression levels of SPC25 in HCC and non-tumorous tissues were comparatively analyzed in R (version 3.6.3) using the limma package ([@ref-18]). Next, the expression data and clinical data were merged using the patients' unique identification numbers. In total, 370 patients were included in the final analysis. The relationship between SPC25 expression and clinical parameters was analyzed in these patients. The patients were classified into high expression and low expression groups based on the median SPC25 expression level in patients with HCC. The differences in the overall survival rates between the two groups were analyzed using R (version 3.6.3) 'survival' package (<https://CRAN.R-project.org/package=survival>). Furthermore, ESTIMATE (Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data) algorithm was used to estimate the tumor purity, and the presence of infiltrating stromal/immune cells in tumor microenvironment for each sample. We analyzed the relationships between SPC25 expression and immune cell infiltration ([@ref-25]).

Statistical analysis
--------------------

The correlation between SPC25 expression and clinicopathological characteristics was evaluated using the Chi-square test and logistic regression and was represented with box plots. The area under the curve (AUC) value obtained from the receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic effectiveness of SPC25 in discriminating HCC tissues from normal tissues in both cohorts using the pROC package ([@ref-19]). An AUC value greater than 0.85 is considered to have outstanding predictive value ([@ref-16]). Kaplan--Meier curves with *P*-value calculated by the log-rank test were used to compare the differences in overall survival rates. The univariate Cox regression analysis was performed to identify the possible prognostic variables. The multivariate Cox analysis was performed to verify the effect of SPC25 expression level on prognosis along with other clinical factors. The variables with *P* \< 0.05 in the univariate analysis were adjusted in the multivariate analysis. A nomogram was established based on the independent clinicopathological factors in TCGA cohort using the 'rms' package (<https://CRAN.R-project.org/package=rms>). The nomogram was validated by analyzing discrimination and calibration curves in both cohorts. The concordance index (C-index) was used to evaluate the discrimination of the nomogram. The decision curve analysis (DCA, <https://CRAN.R-project.org/package=rmda>) was performed to test the clinical utility of the model between the SPC25-based nomogram, the AJCC staging system, and alpha-fetoprotein levels. The differences were considered statistically significant when the *P*-value was less than 0.05. All statistical analyses were performed using the R software (V.3.6.3, <http://www.r-project.org>).

Validation of the diagnostic and prognostic values of SPC25 using an external database
--------------------------------------------------------------------------------------

To obtain reliable results, the mRNA expression profiles of 240 HCC cases and 260 adjacent nontumor tissues with clinical data downloaded from the ICGC database (<https://dcc.icgc.org/projects/LIRI-JP>) were analyzed following the same methodology used to analyze TCGA cohort. Among the ICGC cohort, 202 adjacent nontumor tissues from patients with cancer and 240 primary tumor samples from patients with HCC were included in this study to validate the results of TCGA cohort analysis.

Results
=======

SPC25 expression in patients with varied clinicopathological parameters
-----------------------------------------------------------------------

The correlation between SPC25 expression and clinicopathological characteristics in patients with HCC was represented using the box plots. The clinical data of patients in the internal validation group and the external validation group were shown in [Table 1](#table-1){ref-type="table"}. As shown in [Fig. 1](#fig-1){ref-type="fig"}, high SPC25 expression was associated with patient age (*P* = 0.025, [Fig. 1A](#fig-1){ref-type="fig"}), pathological stage (*P* = 0.004, [Fig. 1C](#fig-1){ref-type="fig"}), histologic grade (*P* \< 0.0001, [Fig. 1D](#fig-1){ref-type="fig"}), survival status (*P* = 0.00029, [Fig. 1E](#fig-1){ref-type="fig"}), and family history of cancer (*P* = 0.01, [Fig. 1G](#fig-1){ref-type="fig"}). However, SPC25 expression was not significantly correlated with sex and vascular invasion (all *P* \> 0.05, [Figs. 1B](#fig-1){ref-type="fig"} and [1F](#fig-1){ref-type="fig"}). The differences in the SPC25 expression level in HCC tissues and non-tumorous tissues were represented using a boxplot. The expression level of SPC25 in HCC tissues was significantly upregulated when compared with that in normal tissues ([Fig. 2A](#fig-2){ref-type="fig"}, *P* \< 0.0001). Next, the expression level of SPC25 in 50 paired HCC tissues and non-neoplastic tissues from TCGA cohort was analyzed. The expression level of SPC25 in HCC tissues was upregulated when compared with that in non-neoplastic tissues ([Fig. 2B](#fig-2){ref-type="fig"}, *P* \< 0.0001).
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###### Clinical data of patients in the internal validation group and the external validation group.

![](peerj-08-9535-g007)

  **Variables**       **Subgroups**   **TCGA**   **ICGC**
  ------------------- --------------- ---------- ----------
  Age                                            
                      \<65            221        85
                      ≥65             149        155
  Sex                                            
                      Male            249        179
                      Female          121        61
  Stage                                          
                      I               171        36
                      II              85         109
                      III             85         74
                      IV              5          21
                      NA              24         0
  Grade                                          
                      I               55         --
                      II              177        --
                      III             121        --
                      IV              12         --
                      NA              5          --
  Survival status                                
                      Dead            130        43
                      Living          240        197
  Vascular invasion                              
                      Positive        108        --
                      Negative        206        --
                      NA              56         --
  Family history                                 
                      Positive        112        76
                      Negative        207        149
                      NA              51         15
  Prior malignancy                               
                      Positive        --         32
                      Negative        --         208
                      NA              --         0

![SPC25 mRNA expression varied significantly in patients with hepatocellular carcinoma (HCC) exhibiting different clinicopathological characteristics.\
The SPC25 expression level was compared between HCC samples and non-tumorous samples in from The Cancer Genome Atlas (TCGA) cohort according to (A) age, (B) gender, (C) pathological stage, (D) histologic grade, (E) survival status, (F) vascular invasion, and (G) family history of cancer.](peerj-08-9535-g001){#fig-1}

![The expression levels and diagnostic and prognostic values of SPC25 in hepatocellular carcinoma.\
(A) The expression level of SPC25 in hepatocellular carcinoma tissues was significantly higher than that in non-tumorous tissues (*P* \< 0.0001). (B) In 50 paired HCC and non-tumorous tissues, the expression level of SPC25 in hepatocellular carcinoma tissues was upregulated when compared with that in adjacent non-tumorous tissues (*P* \< 0.0001). (C) Impact of SPC25 expression on overall survival in patients with hepatocellular carcinoma in The Cancer Genome Atlas (TCGA) cohort. (D) Diagnosis value of SPC25 expression in discriminating hepatocellular carcinoma tissues from non-tumorous tissues.](peerj-08-9535-g002){#fig-2}

Logistic regression analysis revealed that upregulated SPC25 expression in HCC was closely associated with age (odds risk \[OR\] = 0.568 for ≥65 vs \<65, 95% CI \[0.372--0.863\], *P* = 0.0083), pathological stage (OR = 1.957 for stage III + stage IV vs stage I + stage II, 95% CI \[1.202--3.223\], *P* = 0.0075), histologic grade (OR= 4.936 for grade 3 vs grade 1, 95% CI \[2.506--10.104\], *P* \< 0.001; OR= 12.187 for grade 4 vs grade 1, 95% CI \[2.827--85.344\], *P* = 0.0026), and patients survival status (OR = 1.958 for dead vs. alive, 95% CI \[1.272--3.036\], *P* = 0.0024) ([Table 2](#table-2){ref-type="table"}).

Diagnostic and prognostic values of upregulated SPC25 expression in patients with HCC
-------------------------------------------------------------------------------------

The prognostic value of SPC25 in patients with HCC was evaluated. The Kaplan--Meier curve demonstrated that high SPC25 expression was significantly associated with unfavorable overall survival ([Fig. 2C](#fig-2){ref-type="fig"}, *P* \< 0.001). To assess the diagnostic value of SPC25, we generated an ROC curve using the SPC25 expression data from 370 HCC tissues and 50 non-neoplastic tissues. As shown in [Fig. 2D](#fig-2){ref-type="fig"}, SPC25 had an excellent diagnostic value in discriminating HCC tissues from normal tissues with an AUC of 0.969 (95% CI \[0.94.8--0.984\]), sensitivity of 92.78% (95% CI \[89.7--95.2\]%), and specificity of 94.00 (95% CI \[83.5--98.7\]%).

We further explored the expression level of SPC25 in other gastrointestinal tract malignances. As shown in [Fig. 3](#fig-3){ref-type="fig"}, the expression levels of SPC25 in cholangiocarcinoma, colon adenocarcinoma, pancreatic adenocarcinoma, rectum adenocarcinoma, LIHC, and stomach adenocarcinoma were significantly higher than those in non-neoplastic tissues. To confirm the prognostic value of SPC25 expression, univariate and multivariate analyses were performed. The univariate analysis revealed that age, sex, pathological stage, and SPC25 expression were significantly correlated with overall survival (all *P* \< 0.05). After adjusting for other prognostic variables, the multivariate analysis revealed that SPC25 expression was independently associated with overall survival (hazard ratio \[HR\] = 1.76, 95% CI \[1.100--2.815\], *P* = 0.0183). All other independent risk variables, including age and pathological stage, and the corresponding HR and 95% CI are listed in [Table 3](#table-3){ref-type="table"}.
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###### Logistic regression of SPC25 expression associated with clinical pathological characteristics.
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  Clinical characteristics                    Total (*N*)   Odds ratio in SPC25 expression   95% CI          *P*-Value
  ------------------------------------------- ------------- -------------------------------- --------------- --------------
  Pathological stage (III + IV *vs* I + II)   346           1.957                            1.202--3.223    **0.0075**
  Histologic grade (G2 *vs* G1)               232           1.792                            0.946--3.523    0.0802
  (G3 *vs* G1)                                176           4.936                            2.506--10.104   **\<0.0001**
  (G4 *vs* G1)                                67            12.187                           2.827--85.344   **0.0026**
  Age (≥65 *vs* \<65)                         370           0.568                            0.372--0.863    **0.0083**
  Gender (Male *vs* Female)                   370           0.621                            0.542--1.127    0.0854
  Survival status (Dead *vs* Alive)           370           1.958                            1.272--3.036    **0.0024**
  Family history of cancer (Yes *vs* No)      319           0.686                            0.431--1.088    0.11
  Vascular invasion (Yes *vs* No)             314           1.487                            0.932--2.383    0.0969

**Notes.**

Statistically significant *P*-values are given in bold, *P* \< 0.05.

![The expression of SPC25 in colon adenocarcinoma, LIHC, pancreatic adenocarcinoma, stomach adenocarcinoma, rectum adenocarcinoma, cholangiocarcinoma, and corresponding non-tumorous tissues.](peerj-08-9535-g003){#fig-3}
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###### Univariate and multivariate analysis of the relationship of SPC25 expression with overall survival among hepatocellular carcinoma patients.
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  Variables           Univariate analysis   Multivariate analysis                                       
  ------------------- --------------------- ----------------------- ------------ ------- -------------- ------------
  Age                 1.021                 1.002--1.040            **0.0267**   1.02    1.001--1.040   **0.0421**
  Sex                 0.587                 0.373--0.923            **0.0211**   0.796   0.490--1.294   0.358
  Stage               1.465                 1.142--1.879            **0.0027**   1.415   1.097--1.824   **0.0075**
  SPC25               1.776                 1.121--2.814            **0.0144**   1.76    1.100--2.815   **0.0183**
  Grade               1.221                 0.893--1.669            0.2116                              
  Vascular invasion   1.443                 0.904--2.305            0.1244                              
  Family history      1.418                 0.903--2.225            0.1291                              

**Notes.**

SPC25spindle pole body component 25HRhazard ratioCIconfidence interval

Bold values indicate *P* \< 0.05.

Nomogram construction and validation
------------------------------------

Based on the results from multivariate Cox analysis, age, pathological stage, and SPC25 expression were identified as independent prognostic factors for overall survival. Nomograms for predicting 1-, 3-, and 5- year overall survival rates were established based on these independent risk factors in TCGA cohort ([Fig. 4A](#fig-4){ref-type="fig"}). The internal validation in TCGA cohort demonstrated that the C-index of nomogram for overall survival was 0.647 (95% CI \[0.582--0.711\]), which was higher than that of the AJCC staging (C-index = 0.558; 95% CI \[0.494--0.622\]) and alpha-fetoprotein levels (C-index = 0.425, 95% CI \[0.350--0.501\]). In the ICGC cohort, the C-index for nomogram to predict overall survival was 0.805 (95% CI \[0.745--0.864\]), which was higher than that of AJCC staging (C-index = 0.705, 95% CI \[0.634--0.780\]). The calibration plots in TCGA cohort ([Fig. 4B](#fig-4){ref-type="fig"}) and ICGC cohort ([Fig. 4C](#fig-4){ref-type="fig"}) demonstrated an excellent agreement between the nomogram prediction and observed estimates for 1-, 3-, and 5-year overall survival rates. In the DCA analysis, the nomogram presented preferable net benefit with a wider range of threshold probabilities when compared with the AJCC stage system and alpha-fetoprotein levels in both cohorts ([Figs. 4D](#fig-4){ref-type="fig"} and [4E](#fig-4){ref-type="fig"}). These results suggest that the SPC25-based nomogram is superior to the AJCC stage system in predicting HCC prognosis.

![Nomogram for overall survival, calibration plots of the nomogram, and decision curve analysis of nomogram and American Joint Committee on Cancer (AJCC) staging system.\
(A) The nomogram predicted 1-, 3-, and 5-year overall survival rates of patients with hepatocellular carcinoma in The Cancer Genome Atlas (TCGA) cohort. (B) The calibration curves predict 1-, 3-, and 5-year overall survival rates in TCGA cohort. (C) The calibration curves predicting the 1- and 3-year overall survival in the International Cancer Genome Consortium cohort. (D) The predicted survival rates in TCGA cohort by nomogram and AJCC staging system were comparatively analyzed. (E) The predicted survival rates in the International Cancer Genome Consortium cohort by nomogram and AJCC staging system were comparatively analyzed.](peerj-08-9535-g004){#fig-4}

Validation of the diagnostic and prognostic values of SPC25 in the ICGC cohort
------------------------------------------------------------------------------

External validation further confirmed that the expression of SPC25 in HCC tissues was higher than that in adjacent tissues ([Fig. 5A](#fig-5){ref-type="fig"}, *P* \< 0.0001). The Kaplan-Meir analysis revealed that the high SPC25 expression group had an unfavorable prognosis when compared with the low SPC25 expression group ([Fig. 5B](#fig-5){ref-type="fig"}, *P* \< 0.001). The diagnostic value of SPC25 also demonstrated excellent performance in the ICGC cohort with an AUC of 0.945 (95% CI \[0.920--0.965\], [Fig. 5C](#fig-5){ref-type="fig"}). The univariate analysis indicated that SPC25 expression, sex, and pathological stage were correlated with overall survival (all *P* \< 0.005, [Fig. 5D](#fig-5){ref-type="fig"}). After adjusting for other risk factors, the multivariate analysis results confirmed that SPC25 expression was independently correlated with survival in patients with HCC (HR = 6.495, 95% CI \[2.646--15.946\], *P* \< 0.001, [Fig. 5E](#fig-5){ref-type="fig"}). These results indicate that SPC25 is a novel diagnostic and prognostic biomarker for HCC.

Correlation of SPC25 with the proportion of tumor-infiltrating immune cells
---------------------------------------------------------------------------

Furthermore, the correlation of SPC25 expression with the immune microenvironment was explored among 21 kinds of immune cell profiles in LIHC samples. The results from the correlation analyses demonstrated that a total of 3 kinds of tumor-infiltrating immune cells were correlated with the expression of SPC25 ([Fig. 6](#fig-6){ref-type="fig"}). Among them, activated CD4 T memory cells were positively correlated with SPC25 expression ([Fig. 6A](#fig-6){ref-type="fig"}); two kinds of tumor-infiltrating immune cells were negatively correlated with SPC25 expression, including regulatory T cells (Tregs), and resting memory CD4 + T cells ([Figs. 6B](#fig-6){ref-type="fig"}--[6C](#fig-6){ref-type="fig"}). These results further indicated that the levels of SPC25 affected the immune activity of immune microenvironment to a certain extent.

Discussion
==========

In this study, the expression of SPC25 in HCC tissues was upregulated when compared with that in normal tissues. The expression of SPC25 was related to age, pathological stage, histologic grade, survival status, and family history of cancer. The Kaplan--Meier analysis of overall survival revealed that high expression of SPC25 was associated with unfavorable prognosis in patients with HCC. The ROC analysis confirmed that SPC25 had an excellent diagnostic value in discriminating HCC tissues from normal tissues. The univariate and multivariate analyses revealed that upregulated SPC25 expression was an independent prognostic factor of short overall survival. These results were successfully validated in an external (ICGC) cohort. These findings suggest that SPC25 expression can serve as a promising biomarker of poor prognosis in patients with HCC.

![The validation of the expression levels and diagnostic and prognostic values of SPC25 in hepatocellular carcinoma in the International Cancer Genome Consortium cohort.\
(A) The expression level of SPC25 in hepatocellular carcinoma was upregulated when compared with that in normal solid tissues (*P* \< 0.0001). (B) High SPC25 expression was associated with an unfavorable overall survival in patients with hepatocellular carcinoma (*P* \< 0.0001). (C) Diagnosis value of SPC25 expression in hepatocellular carcinoma in the International Cancer Genome Consortium cohort. (D) Univariate analysis and (E) multivariate analysis of the correlation of SPC25 expression with overall survival among patients with hepatocellular carcinoma.](peerj-08-9535-g005){#fig-5}

![Scatter plot showed the correlation of activated CD4 T memory cells (A), regulatory T cells (B), and resting memory CD4 + T cells (C) tumor-infiltrating immune cells proportion with the SPC25 expression (*P* \< 0.05).\
The blue line in each plot was fitted linear model suggesting the proportion of the immune cell along with SPC25 expression, and Pearson coefficient was used for the correlation test.](peerj-08-9535-g006){#fig-6}

SPC25, a key component of the Ndc80 complex, can form a heterodimer with SPC24 to regulate microtubule-kinetochore attachment, chromosome alignment, and spindle checkpoint activation during mitosis process ([@ref-15]; [@ref-20]). Recent studies have reported that the aberrant expression of Ndc80 complex is involved in the progression of human cancer ([@ref-11]; [@ref-12]). Tumorigenesis can result from genetic instability in the cell cycle, which is caused due to defects in chromosomal segregation, a process in which kinetochores play a key role ([@ref-21]). A previous study revealed that SPC25 expression in the basal breast cancer subtype is markedly upregulated when compared with that in other subtypes and that that enhanced SPC25 expression is related to decreased overall survival ([@ref-17]). SPC25 upregulation can increase cancer stem cell properties in lung adenocarcinoma and independently predict poor survival in patients with lung adenocarcinoma. The knockdown of SPC25 impaired the cancer stem cell properties in lung adenocarcinoma ([@ref-5]). A recent study also revealed that SPC25 knockdown promoted the apoptosis of prostate cancer cells ([@ref-8]). These findings demonstrate the potential contribution of SPC25 upregulation to poor survival in HCC.

As the expression of SPC25 plays an important role in overall survival in patients with HCC, we determined whether it can be used to develop an improved prognostic model. A nomogram based on independent prognostic factors was constructed. Compared with the AJCC staging system, the nomogram exhibited an excellent predictive ability in TCGA and ICGC cohorts. Discrimination, calibration, and DCA of the nomogram were verified in the internal and external cohorts. The prognostic nomogram had enhanced performance when compared with the AJCC staging system. Currently, the tumor-node-metastasis (TNM) grading system released by the AJCC is the most commonly used staging system for HCC. However, the efficiency of TNM grading system in prognosis prediction is gradually lost as it is only based on the number of metastatic lymph nodes ([@ref-4]; [@ref-22]). In this study, a nomogram was developed based on the SPC25 expression levels. The nomogram provided a more accurate individualized prediction of overall survival in HCC when compared to the AJCC stage system. This was consistent with a previous SEER-based study on prediction of overall survival and cancer-specific survival in patients with HCC ([@ref-24]).

To the best of our knowledge, this is the first study to demonstrate SPC25 as a useful diagnostic biomarker for HCC, as well as a powerful independent prognostic factor for patients with HCC. However, this study has several limitations. This study only explored the prognostic value of SPC25 based only on the dysregulated mRNA level. The dysregulated protein expression level of SPC25 was not verified. Additionally, the clinical information from TCGA database was not comprehensive. Further clinical data should be included to improve the evaluation of correlation between SPC25 expression and HCC. Furthermore, this study was based on bioinformatics analysis. The in silico findings must be validated by *in vivo* and *in vitro* studies to elucidate the function and mechanism of upregulated SPC25 expression in HCC prognosis.

Conclusion
==========

This study, for the first time, demonstrated that SPC25 expression, which was upregulated in HCC tissues, was correlated with an unfavorable prognosis in patients with HCC using TCGA and ICGC cohorts. SPC25 expression may be a powerful diagnostic and prognostic biomarker for HCC. An SPC25-based nomogram was more accurate and useful than the AJCC staging system.
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